Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 327Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Regulatory requirements for marketing fixed dose combinations

Jayasheel B G

Year : 2010| Volume: 1| Issue : 4 | Page no: 120-123

   This article has been cited by
1 Approaches to Clinical Development of Combination Medicines in the Russian Federation and the Eurasian Economic Union in view of the Requirements of the Current Legislation
A. V. Dobrovolskiy
The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2019; 9(1): 14
[Pubmed]  [Google Scholar] [DOI]
2 Formulation development and evaluation of bi layer tablets: a fixed dose combination of sumatriptan succinate and naproxen sodium as immediate release layer and sumatriptan succinate as delayed release layer
Poluri Koteswari,Srinivasa Babu Puttugunta,Gangadhar Vadlatala
Journal of Pharmaceutical Investigation. 2014;
[Pubmed]  [Google Scholar] [DOI]


Read this article